Rationale for treatment.

Area of Science:

• Cardiology
• Preventive Medicine
• Metabolic Disorders

Background:

• The 1984 NIH Consensus Development Conference established that treating high cholesterol, specifically total and low-density lipoprotein (LDL) cholesterol, can decrease coronary artery disease (CAD) risk.
• The National Cholesterol Education Program (NCEP) developed guidelines in 1988 to categorize CAD risk based on cholesterol levels.
• Numerous clinical trials have substantiated the advantages of antihyperlipidemic therapies in managing cholesterol levels.

Framework:

• The "2:1 ratio" from the Coronary Primary Prevention Trial suggests a 1% reduction in total cholesterol correlates with a 2% decrease in CAD events.
• The Helsinki Heart Study indicated that increasing high-density lipoprotein (HDL)-cholesterol levels may offer additional cardiovascular benefits.
• The Program on the Surgical Control of the Hyperlipidemias demonstrated significant reductions in LDL and total cholesterol, leading to a 35% decrease in CAD events.

Implementation:

• Surgical interventions in the Program on the Surgical Control of the Hyperlipidemias resulted in a two-thirds reduction in coronary bypass operations and angioplasties.
• Long-term studies like the Coronary Drug Project and Multiple Risk Factor Intervention Trial have shown cholesterol-lowering's positive impact on cardiovascular and all-cause mortality.
• The Cholesterol-Lowering Atherosclerosis Study (CLAS) and Familial Atherosclerosis Treatment Study (FATS) documented angiographic improvements, including reduced lesion development and slower progression.

Implications:

• Aggressive antihyperlipidemic therapy, as shown in FATS, may lead to regression of existing arterial lesions in some patients with CAD.
• These findings underscore the critical role of cholesterol management in preventing and treating coronary artery disease.
• Continued research and adherence to guidelines are essential for optimizing cardiovascular health outcomes.